Abbisko Cayman Limited Completes HK$522.5 Million Share Placing to Fund R&D and Corporate Activities – Minichart

Key Highlights of the Announcement

Completion of Share Placement: Abbisko Cayman Limited (Stock Code: 2256) announced the successful completion of a major share placement, raising gross proceeds of approximately HK\$522.5 million through the issuance of 42,900,000 new shares at HK\$12.18 per share.
Increase in Share Capital: The placement represents an approximate 5.99% expansion of the Company’s share capital (excluding treasury shares), enlarging the total issued shares from 673,561,350 to 716,461,350.
Investor Base: The new shares were placed to at least six indepconcludeent third-party investors, none of whom will become a substantial shareholder of the Company as defined under Hong Kong Listing Rules.
Net Proceeds: After deducting fees, costs, and expenses, the Company expects to receive approximately HK\$517.3 million in net proceeds, equating to a net placing price of about HK\$12.06 per share.
Intconcludeed Use of Funds: The Company will allocate approximately 90% (about HK\$465.6 million) of the net proceeds towards the research and development of innovative oncology and non-oncology drug candidates, the advancement of international multi-centre clinical trials, and potential commercialization activities. The remaining 10% (about HK\$51.7 million) will be utilized for general and corporate purposes.

Details for Shareholders and Potential Price-Sensitive Information

This announcement is significant for shareholders and potential investors as it:

Signals strong investor confidence in Abbisko Cayman Limited’s R&D pipeline and its ability to execute international clinical trials and commercialization strategies.
Suggests potential acceleration of the Company’s drug development programs, which could lead to value creation and future growth prospects.
Results in a moderate dilution of existing shares, with the shareholding percentages of the core connected persons decreasing marginally due to the enlarged share base.
Ensures that no single placee or their ultimate beneficial owner will attain substantial shareholder status, thus maintaining a diversified and stable shareholder structure.

Effects on Shareholding Structure

Shareholder	Number of Shares (Before)	% (Before)	Number of Shares (After)	% (After)
Dr. Xu Yao-Chang (Chairman)	79,494,980	11.80%	79,494,980	11.10%
Dr. Yu Hongping	16,496,894	2.45%	16,496,894	2.30%
Dr. Ji Jing	3,814,250	0.57%	3,814,250	0.53%
Placees	–	–	42,900,000	5.99%
Other Public Shareholders	573,755,226	85.18%	573,755,226	80.08%
Total (excluding treasury shares)	673,561,350	100.00%	716,461,350	100.00%

Implications for Investors

Strategic Financing: The successful placement strengthens Abbisko Cayman Limited’s balance sheet, providing substantial resources to pursue its clinical and commercial objectives. This could enhance the Company’s competitiveness and lead to positive catalysts, especially if its R&D assets achieve successful clinical outcomes or commercial launches.
Potential Share Price Impact: While the dilution effect may weigh modestly on the share price in the short term, the capital raised is expected to support medium- to long-term value creation. Investors should monitor the Company’s pipeline progress and any updates on clinical or commercialization milestones, which may influence market sentiment.
Corporate Governance: The shareholding of the core connected persons remains substantial, indicating continued alignment with shareholders and management stability.

Board Composition

As of the date of the announcement, the Board of Abbisko Cayman Limited comprises:

Dr. Xu Yao-Chang (Chairman, Executive Director)
Dr. Yu Hongping (Executive Director)
Dr. Ji Jing (Executive Director)
Dr. Sun Piaoyang (Indepconcludeent Non-Executive Director)
Mr. Sun Hongbin (Indepconcludeent Non-Executive Director)
Ms. Chui Hoi Yam (Indepconcludeent Non-Executive Director)

Disclaimer: This article is based on publicly available information from Abbisko Cayman Limited’s official announcement regarding the completion of a share placement. The information herein does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before building any investment decisions. The Company has not registered any of the placed securities under the U.S. Securities Act and does not intconclude to conduct a public offering in the United States.